Mechanisms of Berberine for the Treatment of Atherosclerosis Based on Network Pharmacology
Related Experiment Video
Updated: Dec 24, 2025

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
Xuejiao Xie1, Xingyu Ma1, Siyu Zeng1
1Department of Zhongjing Theory, College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
Abstract:
Atherosclerosis is a common metabolic disease characterized by lipid metabolic disorder. The processes of atherosclerosis include endothelial dysfunction, new endothelial layer formation, lipid sediment, foam cell formation, plaque formation, and plaque burst. Owing to the adverse effects of first-line medications, it is urgent to discover new medications to deal with atherosclerosis. Berberine is one of the most promising natural products derived from traditional Chinese medicine. However, the panoramic mechanism of berberine against atherosclerosis has not been discovered clearly. In this study, we used network pharmacology to investigate the interaction between berberine and atherosclerosis. We identified potential targets related to berberine and atherosclerosis from several databases. A total of 31 and 331 putative targets for berberine and atherosclerosis were identified, respectively. Then, we constructed berberine and atherosclerosis targets with PPI data. Berberine targets network with PPI data had 3204 nodes and 79437 edges. Atherosclerosis targets network with PPI data had 5451 nodes and 130891 edges. Furthermore, we merged the two PPI networks and obtained the core PPI network from the merged PPI network. The core PPI network had 132 nodes and 3339 edges. At last, we performed functional enrichment analyses including GO and KEGG pathway analysis in David database. GO analysis indicated that the biological processes were correlated with G1/S transition of mitotic cells cycle. KEGG pathway analysis found that the pathways directly associated with berberine against atherosclerosis were cell cycle, ubiquitin mediated proteolysis, MAPK signaling pathway, and PI3K-Akt signaling pathway. After combining the results in context with the available treatments for atherosclerosis, we considered that berberine inhibited inflammation and cell proliferation in the treatment of atherosclerosis. Our study provided a valid theoretical foundation for future research.
Insights
Berberine shows promise in treating atherosclerosis by inhibiting inflammation and cell proliferation. This study used network pharmacology to uncover berberine
Area of Science:
- Pharmacology and Traditional Chinese Medicine
- Cardiovascular Disease Research
- Systems Biology Approaches
Background:
- Atherosclerosis is a metabolic disease involving lipid disorders and plaque formation.
- Current treatments for atherosclerosis have adverse effects, necessitating new therapeutic options.
- Berberine, a natural product from traditional Chinese medicine, is a potential candidate for atherosclerosis treatment.
Purpose of the Study:
- To investigate the comprehensive mechanism of berberine in treating atherosclerosis using network pharmacology.
- To identify key molecular targets and pathways involved in berberine's action against atherosclerosis.
- To provide a theoretical basis for berberine as a novel therapeutic agent for atherosclerosis.
Main Methods:
- Network pharmacology was employed to analyze interactions between berberine and atherosclerosis.
- Databases were used to identify berberine and atherosclerosis-related targets.
- Protein-protein interaction (PPI) networks were constructed and merged to find core targets.
- Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed.
Main Results:
- A total of 31 berberine targets and 331 atherosclerosis targets were identified.
- A core PPI network with 132 nodes and 3339 edges was constructed.
- Functional enrichment analysis revealed associations with cell cycle regulation (G1/S transition).
- Key KEGG pathways included cell cycle, ubiquitin-mediated proteolysis, MAPK, and PI3K-Akt signaling.
Conclusions:
- Berberine appears to exert its anti-atherosclerosis effects by modulating cell cycle progression and inhibiting inflammation.
- The identified pathways provide insights into berberine's therapeutic mechanisms.
- This study supports berberine as a promising natural compound for atherosclerosis treatment.
More Related Videos
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
12:34Author Spotlight: Exploring ShiDuGao's Multi-Target Approach in Anus Eczema Treatment
Published on: January 12, 2024
Related Concept Videos
Atherosclerosis III: Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Atherosclerosis I: Introduction
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Atherosclerosis IV: Nursing Management
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....